Thoracic Cancer最新文献

{"title":"Prognostic Significance, Radiological, and Metabolic Characteristics of Metastatic Lymph Nodes in Resectable Non-Small Cell Lung Cancer Following Neoadjuvant Chemoimmunotherapy.","authors":"Tianxiao Han, Sida Cheng, Xun Wang, QingYi Qi, Jinchuan Chen, Wenxiang Wang, Jian Zhou, Yun Li, Kezhong Chen, Hao Li, Fan Yang","doi":"10.1111/1759-7714.70073","DOIUrl":"https://doi.org/10.1111/1759-7714.70073","url":null,"abstract":"<p><strong>Background: </strong>Metastatic lymph nodes (mLNs) exhibit different responses to neoadjuvant immunotherapy compared to the primary tumor (PT) in non-small cell lung cancer (NSCLC). Evaluating mLNs' response is crucial for predicting treatment efficacy and prognosis; however, such assessments are currently insufficient.</p><p><strong>Methods: </strong>We enrolled 101 NSCLC patients with mLNs who underwent neoadjuvant chemoimmunotherapy followed by surgery. Survival outcomes and radiological and metabolic changes were analyzed across different lymph node pathological response groups, and a least absolute shrinkage and selection operator (LASSO) logistic regression model was developed to predict mLNs' response. RNA sequencing was performed to characterize the immune microenvironment of lymph nodes with different pathological responses.</p><p><strong>Results: </strong>Residual tumors in mLNs were significantly associated with worse recurrence-free survival (p = 0.003) and a trend toward worse overall survival (p = 0.087). Combining the pathological responses of mLNs and PTs improved prognostic stratification. Neither radiological size changes (AUC: 0.621) nor the SUVmax reduction rate (AUC: 0.645) were effective in distinguishing mLNs response. A model combining radiological and metabolic parameters demonstrated fair prediction efficacy (AUC: 0.85). In separate analyses of N1 and N2 nodes, radiological and metabolic changes of N1 mLNs partly reflected their pathologic response (AUC: 0.734; 0.816), unlike in N2 mLNs. RNA sequencing revealed that immune infiltration in responding lymph nodes differed from non-responding ones, with higher CD8+ T cells, NK T cells, B cells, and dendritic cells in the former.</p><p><strong>Conclusion: </strong>The pathological response of mLNs provides additional prognostic information, but current tools are ineffective for detecting residual tumors. A model integrating radiological and metabolic parameters may offer better prediction.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 9","pages":"e70073"},"PeriodicalIF":2.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epithelial-Mesenchymal Plasticity in the D-Meso-Sonobe Mesothelioma Cell Line: A Putative Model of Epithelial-Mesenchymal Transition in Mesothelioma.","authors":"Hiroshi Okubo, Yuki Hanamatsu, Chiemi Saigo, Sonobe Hiroshi, Tamotsu Takeuchi","doi":"10.1111/1759-7714.70091","DOIUrl":"10.1111/1759-7714.70091","url":null,"abstract":"<p><p>Epithelial-mesenchymal transition (EMT) plays a crucial role in carcinogenesis, including mesothelioma. D-Meso-Sonobe is a deciduoid-type mesothelioma cell line with morphological features similar to those of epithelioid cells. Here, we report that D-Meso-Sonobe cells exhibit spindle cell mesenchymal features under continuous confluent culture conditions. The spindle cell mesenchymal D-Meso-Sonobe expresses zinc finger E-box-binding homeobox 1 (Zeb1), which is a master regulator of EMT in the nucleus. Xenoplanted D-Meso-Sonobe cells expressed nuclear Zeb1 and yes-associated protein at the cancer invasion front and focally expressed integrin subunit alpha V and actin alpha 2, which are molecular phenotypes acquired by EMT in mesothelioma. Subsequent RNA sequencing revealed that lysyl oxidase like 1 (LOXL1) was more highly expressed in cultured spindle mesenchymal D-Meso-Sonobe cells than in epithelioid cells. LOXL1 immunoreactivity was observed at the invasive front of xenoplanted D-Meso-Sonobe cells. The epithelial-mesenchymal plasticity of D-Meso-Sonobe cells may be applicable for the development of candidate molecular agents targeting EMT in mesothelioma.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 10","pages":"e70091"},"PeriodicalIF":2.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Outcome of Thoraco-Laparoscopic McKeown Esophagectomy Versus Endoscopic Submucosal Dissection for Early-Stage Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis.","authors":"Ping Yuan, Zhenhao Huang, Feichao Bao, Jiajing Li, Lidong Chen, Hongtao Wen, Donglei Liu, Feng Li, Shanfeng Zhang, Yu Qi, Xiangnan Li","doi":"10.1111/1759-7714.70064","DOIUrl":"https://doi.org/10.1111/1759-7714.70064","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate thoraco-laparoscopic McKeown esophagectomy (TLME) versus endoscopic submucosal dissection (ESD) for clinical-T1N0 esophageal squamous cell carcinoma (ESCC) depending on invasion depth.</p><p><strong>Background: </strong>Early-stage ESCC has been widely treated by endoscopic resection. While ESD is safer than esophagectomy perioperatively, its survival benefits for clinical-T1N0M0 ESCC, especially high-risk T1b tumors, are unclear.</p><p><strong>Methods: </strong>A retrospective study was conducted on clinical-T1N0 ESCC patients at the First Affiliated Hospital of Zhengzhou University comparing TLME (cT1a, n = 352; cT1b, n = 205) with ESD (cT1a, n = 499; cT1b, n = 62). Overall survival (OS), disease-specific survival (DSS), relapse-free survival (RFS), and metastasis-free survival (MFS) were analyzed depending on invasion depth after propensity score matching to account for selection bias.</p><p><strong>Results: </strong>ESD group had better OS (hazard ratio: 0.54, p = 0.029) but worse RFS (hazard ratio: 6.83, p < 0.001) than TLME group in general terms. T1a cancers showed no difference in DSS and MFS between groups. T1b subgroup with ESD had lower DSS (hazard ratio: 5.65, p = 0.036) and MFS (hazard ratio: 3.54, p = 0.069). R1-resection in ESD group linked to poorer OS (hazard ratio: 5.89, p = 0.006) and DSS (hazard ratio: 3.67, p = 0.006).</p><p><strong>Conclusion: </strong>ESD can be safe in the treatment of clinical-T1aN0 ESCC. However, concerning oncologic curability, TLME should be recommended for patients with clinical-T1bN0 ESCC in terms of favorable DSS, RFS, and MFS.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 9","pages":"e70064"},"PeriodicalIF":2.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Awareness of Venous Thromboembolism in Patients With Cancer and Their Carers: Protocol for Systematic Review.","authors":"Ann-Rong Yan, Gregory M Peterson, Mark Naunton, Phillip Newman, Murray R Turner, Desmond Yip, Nasser Bagheri, Reza Mortazavi","doi":"10.1111/1759-7714.70093","DOIUrl":"10.1111/1759-7714.70093","url":null,"abstract":"<p><strong>Background: </strong>There is an increased risk of venous thromboembolism (VTE) for people living with cancer. However, the awareness of VTE in this population or their carers appears to be low. This lack of awareness may lead to poor outcomes, such as VTE due to low adherence to thromboprophylaxis or delayed hospital presentations with neglected VTE symptoms. This study protocol will guide researchers in conducting a systematic review of existing studies (quantitative, qualitative, or mixed methods) which have assessed VTE awareness among patients living with cancer or their carers. It will also investigate the rates and predictors of VTE awareness in those populations.</p><p><strong>Methods: </strong>This protocol was designed following the PRISMA-P 2015 statement and the methodological guidance from the PRISMA 2020 statement. Six databases (APA PsycINFO, CINAHL, Google Scholar, Medline, Scopus, and Web of Science Core Collection) will be searched to retrieve all eligible studies. Covidence software will be utilized to assist in the screening of studies for eligibility. A standard data extraction form will be used, and the Mixed Methods Appraisal Tool (MMAT) will be used to assess the methodological quality of each included study. Both a qualitative descriptive approach and meta-analysis will be used for data synthesis and integration where possible. The protocol has been registered with PROSPERO (CRD42025628429).</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 10","pages":"e70093"},"PeriodicalIF":2.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline and changes in inflammatory parameters for patients with EGFR-mutated NSCLC treated with afatinib.","authors":"Zi-Ting Chang, Ping-Chih Hsu, How-Wen Ko, John Wen-Cheng Chang, Chen-Te Wu, Chen-Yang Huang, Ching-Fu Chang, Chih-Hsi Scott Kuo, Cheng-Ta Yang, Chiao-En Wu","doi":"10.1111/1759-7714.15338","DOIUrl":"https://doi.org/10.1111/1759-7714.15338","url":null,"abstract":"<p><strong>Background: </strong>This study investigated the relationship between inflammatory biomarkers (lymphocyte ratio [NLR], monocyte-to-lymphocyte ratio [MLR], and platelet-to-lymphocyte ratio [PLR]) and the treatment outcomes of patients with non-small cell lung cancer (NSCLC) treated with afatinib.</p><p><strong>Methods: </strong>The patients with NSCLC treated with afatinib between June 2014 and February 2018 were retrospectively reviewed. Their inflammatory biomarkers and clinical outcomes (progression-free survival [PFS] and tumor response) were explored using univariate and multivariate analyses.</p><p><strong>Results: </strong>Among 325 patients, those with an NLR >2.18, MLR >0.19, and PLR >177.73 had significantly worse PFS than those with lower values. After adjusting for performance status, stage, and liver metastasis, the PFS was still unfavorable for a baseline NLR >2.18, MLR >0.19, or PLR > 177.73. Among 188 patients with paired inflammatory values, those whose NLR decreased by >29.5%, MLR decreased by >57.9%, and PLR increased by <18.8% had significantly better PFS. After adjusting for performance status, stage, and liver metastasis, the PFS was significantly unfavorable for an NLR decrease of <29.5% and MLR decrease of <57.9%. Among the patients with tumor response, NLR, MLR, and PLR significantly decreased after treatment (all p < 0.05).</p><p><strong>Conclusions: </strong>Our study presented the NLR, MLR, and PLR as prognostic factors for patients with NSCLC treated with afatinib. Further investigation into these markers representing the tumor microenvironment and their association with cancer status is crucial for evaluating prognosis and clinical outcomes in patients with NSCLC.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of immunotherapy remained in patients with recurrent/metastatic non-small-cell lung cancer after surgery with or without postoperative thoracic radiotherapy: a bi-center retrospective study.","authors":"Yuqi Wu, Renda Li, Fengwei Tan, Jianzhong Cao, Nan Bi","doi":"10.1111/1759-7714.15384","DOIUrl":"https://doi.org/10.1111/1759-7714.15384","url":null,"abstract":"<p><strong>Purpose: </strong>Since mediastinal lymph node dissection and radiotherapy (RT) have potential unclear impacts on pulmonary lymphatic system, this study aimed to assess the effectiveness of immune checkpoint inhibitors (ICIs) in recurrent/metastatic non-small-cell lung cancer (NSCLC) patients who previously received radical surgery with or without thoracic RT.</p><p><strong>Methods: </strong>Clinical data of patients who underwent pulmonary lobectomy with systematic lymphadenectomy (2000.1.1-2021.7.2) and received immunotherapy after progression were retrospectively analyzed. Efficacy was mainly evaluated based on progression-free survival (PFS) from the start of the ICIs. Toxicity was defined as treatment discontinuation due to immune-related adverse effects (irAEs).</p><p><strong>Results: </strong>Ninety-five patients were enrolled in the final cohort and 30 (31.6%) patients received thoracic RT before ICI treatment. ICIs were administered as a first-line systematic treatment in 52.6% of patients. The median follow-up time was 14.7 months (95% confidence interval [CI] 13.3-18.7 months). The median PFS was 12.3 months (95% CI 8.5-36.6 months). Six (6.3%) patients had treatment suspended due to irAEs. Patients who received RT had comparable median PFS with the non-RT group (17.0 months vs. 11.1 months, p = 0.16). Similar toxicity rates were observed. Similar mPFS were reported in the stage III subgroup (RT vs. non-RT, 8.10 vs. 8.45 months, p = 0.86) or the subgroup treated by ICIs as primary systematic therapy (RT vs. non-RT, 13.6 vs. 16.1 months, p = 0.45).</p><p><strong>Conclusions: </strong>ICIs remained effective in recurrent/metastatic NSCLC patients with radical surgery and RT did not significantly compromise therapeutic effects.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polymeric Micellar Paclitaxel Plus Cisplatin Combined With Tislelizumab as the First-Line Treatment of Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study.","authors":"Xiaoyou Li, Jiamin Shi, Jinghua Zhu, Jingni Zhu, Fei Yan, Delin Liu, Guochun Cao","doi":"10.1111/1759-7714.70055","DOIUrl":"https://doi.org/10.1111/1759-7714.70055","url":null,"abstract":"<p><strong>Background: </strong>The current standard treatment for advanced and metastatic esophageal squamous cell carcinoma (ESCC) involves a combination of immunotherapy and chemotherapy, but paclitaxel's hormone preconditioning can reduce immune response and effectiveness. Polymeric micellar paclitaxel (Pm-Pac), a nanoformulation, bypasses this issue, enhancing tumor permeability and retention. While Pm-Pac has shown promise in non-small cell lung cancer, its efficacy in ESCC is yet to be established.</p><p><strong>Methods: </strong>This is a prospective phase II trial involving untreated stage IV ESCC receiving two cycles of Pm-Pac, cisplatin, and tislelizumab. If no disease progression was observed, they received two additional cycles followed by a year of tislelizumab maintenance. Each 3-week cycle consisted of Pm-Pac (230 mg/m²), cisplatin (70 mg/m²), and tislelizumab (200 mg) on Day 1. The main objective was ORR. Secondary endpoints encompassed OS, PFS, DCR, and safety.</p><p><strong>Results: </strong>Between September 1, 2022, and June 30, 2024, 23 patients were included in the study. The median follow-up period was 14.8 months. The ORR stood at 69.6% (95% CI: 0.45-0.84) with a DCR of 100% (95% CI: 0.86-1.00). Out of the patients, 2 experienced complete responses, 14 had partial responses, and 7 maintained stable diseases. The mPFS was 10.8 months (95% CI: 0.26-0.632). The 1-year OS rate was 69.6% (95% CI: 49.1-84.4). Notably, no grade 3 or higher treatment-related adverse events or treatment-linked fatalities were reported.</p><p><strong>Conclusions: </strong>The combination of Pm-Pac, cisplatin, and tislelizumab as an initial therapy for advanced ESCC is safe and effective and should be tested on a larger scale in the future.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Registry: ChiCTR2400088576.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 7","pages":"e70055"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11996230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastasis of Small Cell Lung Cancer to the External Auditory Canal: A Case Report.","authors":"Toshiyuki Ito, Masamichi Yoshida, Hiroto Miki, Hiroki Goto, Shuuji Kodama, Atsushi Fujiwara, Hajime Fujimoto, Tetsu Kobayashi","doi":"10.1111/1759-7714.70059","DOIUrl":"10.1111/1759-7714.70059","url":null,"abstract":"<p><p>Patients with lung cancer often develop distant metastases; however, metastasis to the external auditory canal is rare. We report the case of a 77-year-old man who presented with left-sided hearing loss, otalgia, and a red mass in the left external auditory canal. Computed tomography revealed masses in the left external auditory canal, lung, and pancreas. Histopathological analysis confirmed small cell lung cancer, with thyroid transcription factor 1 positivity in multiple lesions, suggesting a primary tumor in lung. Treatment with carboplatin and etoposide led to a reduction in metastatic lesions, including those in the external auditory canal, and improved hearing impairment. This case highlights a rare instance in which chemotherapy improved ear symptoms in a patient with small cell lung cancer metastasis to the external auditory. Written informed consent was obtained from the patient for the publication of this case report and accompanying images.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 7","pages":"e70059"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival and Perioperative Outcomes After Addition of Immunotherapy to Neoadjuvant Chemoradiotherapy for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma.","authors":"Canjun Li, Xin Wang, Lei Deng, Jianyang Wang, Tao Zhang, Wenqing Wang, Wenyang Liu, Jima Lv, Qinfu Feng, Zongmei Zhou, Xiankai Chen, Ruixiang Zhang, Jianjun Qin, Yin Li, Nan Bi","doi":"10.1111/1759-7714.70054","DOIUrl":"10.1111/1759-7714.70054","url":null,"abstract":"<p><strong>Background: </strong>Currently, neoadjuvant chemoradiotherapy combined with immunotherapy (NCRI) for patients with locally advanced esophageal squamous cell carcinoma (ESCC) is attracting attention. The purpose of this study was to compare the surgical outcomes and survival between patients receiving NCRI and neoadjuvant chemoradiotherapy (NCRT) followed by surgery.</p><p><strong>Methods: </strong>This study retrospectively included patients with locally advanced ESCC and treated with NCRI or NCRT followed by esophagectomy. Two groups were compared for pathologic complete response (pCR) rate, R0 resection rate, and 3-year recurrence-free survival (RFS). Surgery time, the number of lymph nodes removed, postoperative complications, and 30-day mortality were also compared. Propensity score matching (PSM) was performed to minimize the potential impact of confounding factors.</p><p><strong>Results: </strong>After PSM, patients in the NCRI group showed a significantly higher pCR rate compared with those in the NCRT group (54.2% vs. 27.1%, p = 0.046). R0 resection rate (100% vs. 89.6%, p = 0.251), surgery time (p = 0.614), the number of lymph nodes removed (p = 0.526), the incidence of total postoperative complications (46.4% vs. 37.9%, p = 0.564) and 30-day mortality (3.6% vs. 1.1%, p = 0.983) were comparable between the two groups. The NCRI group exhibited a significantly higher 3-year RFS rate compared to the NCRT group (79.2% vs. 62.5%, p = 0.032).</p><p><strong>Conclusion: </strong>For patients with locally advanced ESCC, NCRI showed a significantly higher pCR rate than conventional NCRT, without increased operative risk. NCRI followed by surgery exhibited a superior RFS compared to NCRT followed by surgery. Prospective studies are needed in the future.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 7","pages":"e70054"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral Metachronous Typical and Atypical Carcinoid Tumors of the Lung.","authors":"Alberto Busetto, Giovanni Maria Comacchio, Vincenzo Verzeletti, Fares Shamshoum, Francesco Fortarezza, Federica Pezzuto, Andrea Dell'Amore, Fiorella Calabrese, Federico Rea","doi":"10.1111/1759-7714.70078","DOIUrl":"https://doi.org/10.1111/1759-7714.70078","url":null,"abstract":"<p><p>Bronchial carcinoids are uncommon neuroendocrine tumors. According to their pathological differentiation, they are divided into typical and atypical forms, with diverse biological behavior and aggressiveness. Bronchial carcinoids may be associated with familial neuroendocrine syndromes, such as MEN-1. They can also present initially as diffuse hyperplastic proliferation of neuroendocrine foci throughout the pulmonary parenchyma (DIPNECH). Metachronous and bilateral forms are sporadic in the literature. We describe a case of a 68-year-old man with metachronous bilateral typical-atypical carcinoid neoplasms. The patient was treated with a two-stage mini-invasive pulmonary surgery in a time frame of 5 years. This case may be unique because it features two rare and distinct pathological entities in the same patient, not associated with any known genetic mutation. Carcinoid tumors require multidisciplinary care and a collaborative approach due to their pleomorphic behavior, ensuring comprehensive management and maximizing therapeutic efficacy.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 8","pages":"e70078"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}